Roche reported positive Phase II topline data showing that its once-weekly dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist CT-388 achieved substantial, sustained, and dose-dependent weight loss through 48 weeks Roche reported positive topline results from its Phase II clinical trial, CT388-103, evaluating CT-388, Roches investigational dual glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist being developed for the treatment of obesity
Nausea was the most common and occurred in 13.27%, 17.89%, and 24.08% of study participants taking the 5mg, 10mg, and 15mg doses, respectively
Point of care ultrasonography can be used to assess risks in patients who do not follow dietary restrictions and in patients who describe gastrointestinal symptoms on the day of the procedure
To release the clumps, give your packaging bags a good shake or knock it against the counter or Simply place the sealed packaging bags in the freezer for 30 minutes to restore them
The abdomen also tends to have less nerve density than the thigh at the specific insertion points used, which translates to less sensation during injection
[DOI] [PubMed] [Google Scholar] 47.Rottlaender D., Motloch L., Reda S., Larbig R., Hoppe U
